Kevin J McNamara

CEO Kevin McNamara sells 2,000 shares at CHE; his sixth sale at this company in 36 months, continuing a pattern of net dispositions.

Kevin McNamara, Chemed's President and CEO, sold 2,000 shares, representing his sixth open-market sale at this company in the past 36 months. Over the same period, he has made no open-market purchases, painting a consistent picture of net selling. The stock currently trades well below its 52-week high, and the company remains profitable with solid revenue growth. McNamara's track record at Chemed has been mixed: at the 30-day horizon, three of his five prior sales saw the stock decline afterward (well-timed exits), while two saw gains (poorly-timed); at the 90-day horizon, only one of his five prior sales was followed by a decline, while four saw subsequent stock gains, meaning most prior exits were ultimately poorly timed. This ongoing sale comes at a time when the company's fundamentals remain intact, but the repeated selling pattern combined with mixed timing on prior exits suggests no clear conviction signal from the CEO level.

CEO McNamara sells 1,500 shares of CHE at $369.37; stock down 39.6% from 52-week high, prior sell-timing mixed at this ticker.

Kevin J. McNamara, president and CEO of Chemed, sold 1,500 shares at $369.37 on 2026-03-27, reducing his stake from 93,719 to 92,219 shares. The stock is currently trading at $374.09, down 39.6% from its 52-week high of $619.21 and down 8.8% over the past 30 days. At the same-ticker level, McNamara's prior four measurable sales at CHE show mixed timing results: two were well-timed (negative 90-day returns after the sale), while two were poorly timed (positive returns followed). His cross-ticker track record across 16 prior open-market sales shows a 53.33% well-timed rate, only modestly better than random timing. The modest sale size (-1.6% of holdings) and recent repeated selling activity (another sale just 15 days prior on 2026-03-12) against the backdrop of sustained stock underperformance merit monitoring for any shift in management's forward outlook.

CHE CEO Kevin McNamara sold 2,000 shares at $403.18 on 2026-03-12; stock down -35.1% from 52-week high.

Kevin McNamara, president and CEO of CHEMED CORP, sold 2,000 shares for $806,360.00, reducing his holdings from 95,719 to 93,719 shares. The sale occurred at $403.18, while the stock currently trades at $401.87, down 35.1% from its 52-week high of $619.21 and off 13.2% in the past 30 days. McNamara's cross-ticker track record shows 15 prior sells with a 53.33% well-timed rate at the 90-day mark, but his same-ticker history at CHE is mixed: 3 of 5 prior sales have resulted in positive 90-day returns (poorly timed sells), while 2 showed declines afterward (well-timed). The sale represents a modest 2.1% reduction in his CHE position while the company maintains solid fundamentals with $624.9M quarterly revenue, $64.2M net income, and a 22.86 P/E ratio. Investors should note the stock's recent sharp decline and assess whether this sale reflects operational concerns or routine portfolio management.

CEO McNamara sells 2,000 CHE shares at $437.55; stock down 28.8% from 52-week high.

Kevin J McNamara, president and CEO of Chemed Corp, sold 2,000 shares for $875,100.00 on 2025-11-24, reducing his holdings from 96,197 to 94,197 shares. The sale occurred at $437.55 per share, which is below the current price of $440.70 but represents a significant discount from the 52-week high of $619.21 (28.8% below peak). At this ticker, McNamara's prior four measurable same-ticker sales show a 75% well-timed rate (3 of 4 exhibited negative 90-day returns), suggesting a pattern of selling ahead of declines; however, the current sale's timing cannot yet be assessed. Chemed's fundamentals remain solid with revenue of $624.9M and net income of $64.2M in the latest quarter, supporting a P/E of 22.39, though annual revenue growth of 7.4% is moderate. The sale represents a small reduction (2.1% of pre-transaction holdings), typical of routine portfolio management for a CEO holding 94.2K shares.

CHE CEO McNamara sold 3,000 shares at $461.28; stock down 27.0% from 52-week high, held 96.2K post-trade.

Kevin J McNamara, president and CEO of Chemed Corp, sold 3,000 shares on 2025-09-26 at $461.28, reducing his holdings from 99.2K to 96.2K shares. The sale occurred as the stock trades 27.0% below its 52-week high of $619.21, and notably, his four prior sales at CHE all showed negative 90-day returns (ranging from -4.6% to -27.5%), suggesting his prior exit timing at this ticker has been well-executed relative to subsequent price declines. The company's fundamentals remain solid with a $6.6B market cap, 7.4% annual revenue growth, and P/E of 22.69, making this sale noteworthy for its timing pattern rather than any apparent distress signal. However, the stock has declined 1.3% over 30 days and 6.6% over 90 days, and McNamara retains substantial holdings (96.2K shares), indicating no broad liquidation despite the historically advantageous sale timing.

CHE CEO McNamara sells 2,000 shares at $428.55; stock down 30.9% from 52-week high, down 9.5% in 30d.

Kevin J McNamara, president and CEO of Chemed Corp, sold 2,000 shares on 2025-08-05 at $428.55, reducing holdings from 101,197 to 99,197 shares. The stock has declined significantly from its 52-week high of $619.21, trading at $428.08 (−30.9% from peak) and down −9.5% over the prior 30 days. His prior trades at CHE show a strong pattern: all 5 prior sales resulted in negative 90-day returns, with an average 90-day decline of −11.6% and a 100% well-timed rate. This current sale follows a similar backdrop—stock weakness and the insider's established history of selling into downward momentum at this ticker—though the small share count (2.0K shares, −2.0% of prior holdings) suggests a modest transaction relative to his position size and the company's $6.2B market cap.

CHE CEO Kevin McNamara sold 1,500 shares ($864.7K) on 2025-05-05; his prior 5 CHE trades 3 of 3 well-timed at 90-day mark.

Kevin McNamara, president and CEO of CHEMED CORP, sold 1,500 shares at $576.45 on 2025-05-05, reducing his holdings to 101,197 shares. Notably, his prior five trades at CHE show a disciplined pattern: three measurable 90-day outcomes (2024-11-25, 2024-09-26, 2024-08-05) all resulted in negative returns of -4.6%, -13.2%, and -6.7% respectively, meaning he sold ahead of declines. His cross-ticker track record shows a 44.44% well-timed rate on 11 prior sales across all holdings. The current stock price of $576.51 is -6.9% from the 52-week high and recently declined -3.5% over 30 days, placing this sale in a context where the insider's historical pattern has been to exit ahead of weakness.

CHE CEO McNamara sells 1,000 shares (1.0K) at $615.33; retains 101.7K shares post-transaction.

McNamara sold 1,000 shares on 2025-03-31 at $615.33, representing a 1.0% reduction in his 102.7K share base. The sale occurred near the stock's 52-week high ($644.26), with the current price at $618.56 still elevated and the stock up 3.0% over the prior 30 days. At his same-ticker level, McNamara has executed 5 prior sales at CHE; 3 of the 4 measurable outcomes showed negative 90-day returns, indicating a pattern of well-timed sells at this ticker. His cross-ticker track record shows a 44.44% well-timed rate with average 90-day returns of +0.8%, suggesting modest historical accuracy. The modest sale size and retained position of 101.7K shares indicate the CEO maintains substantial exposure to the company, limiting any inference of conviction shift from a single 1.0% portfolio reduction.

CHE President/CEO McNamara sells 2,000 shares for $1.2M; stock up 5.8% in 30 days post-sale

Kevin J McNamara, president and CEO of Chemed Corp, sold 2,000 shares at $593.67 on March 6, 2025, leaving him with 102,679 shares. The sale reduced his position by less than 2% and occurred when the stock was 8.4% below its 52-week high of $650.70. In the 30 days following this sale, CHE appreciated 5.8%, suggesting this particular trade was not prescient of a near-term decline. Across his prior five trades at Chemed, McNamara sold at times when 60% of those subsequent 90-day periods saw negative returns, indicating some historical success in anticipating downside; however, this current sale's early performance contradicts that pattern.

CHE CEO McNamara sells 2,000 shares at $572.77; stock down -4.9% in 30 days, -11.9% from 52-week high.

Kevin J McNamara, president and CEO of CHEMED CORP, sold 2,000 shares on 2024-11-25 for $1,145,540.00, reducing his holdings from 103,735 to 101,735 shares. The sale occurred as the stock trades at $573.45, down 4.9% over the past 30 days and 11.9% from its 52-week high of $650.70. Examining McNamara's prior transactions at CHE, his 5 prior trades show mixed timing results: only 1 of 4 measurable 90-day outcomes was well-timed (positive 90d return indicating the stock rose after he sold). His cross-ticker track record shows a 28.57% well-timed rate across 8 sells, which is modest. The current sale represents a modest 1.9% reduction in holdings, suggesting measured position management rather than an aggressive de-risking signal.